JP2022501441A - 癌を治療する方法 - Google Patents

癌を治療する方法 Download PDF

Info

Publication number
JP2022501441A
JP2022501441A JP2021540786A JP2021540786A JP2022501441A JP 2022501441 A JP2022501441 A JP 2022501441A JP 2021540786 A JP2021540786 A JP 2021540786A JP 2021540786 A JP2021540786 A JP 2021540786A JP 2022501441 A JP2022501441 A JP 2022501441A
Authority
JP
Japan
Prior art keywords
compound
formula
cancer
therapeutically effective
effective amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2021540786A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022501441A5 (enExample
Inventor
マイク・サテーヘ
アリソン・エイ・アーマー
リチャード・メスマン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mike Sathekge
Endocyte Inc
Original Assignee
Mike Sathekge
Endocyte Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mike Sathekge, Endocyte Inc filed Critical Mike Sathekge
Publication of JP2022501441A publication Critical patent/JP2022501441A/ja
Publication of JP2022501441A5 publication Critical patent/JP2022501441A5/ja
Priority to JP2024135623A priority Critical patent/JP2024178159A/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/0472—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0402—Organic compounds carboxylic acid carriers, fatty acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
JP2021540786A 2018-09-21 2019-09-20 癌を治療する方法 Withdrawn JP2022501441A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024135623A JP2024178159A (ja) 2018-09-21 2024-08-15 癌を治療する方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862734649P 2018-09-21 2018-09-21
US62/734,649 2018-09-21
PCT/US2019/052161 WO2020061458A1 (en) 2018-09-21 2019-09-20 Methods of treating cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024135623A Division JP2024178159A (ja) 2018-09-21 2024-08-15 癌を治療する方法

Publications (2)

Publication Number Publication Date
JP2022501441A true JP2022501441A (ja) 2022-01-06
JP2022501441A5 JP2022501441A5 (enExample) 2022-09-29

Family

ID=69887889

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021540786A Withdrawn JP2022501441A (ja) 2018-09-21 2019-09-20 癌を治療する方法
JP2024135623A Pending JP2024178159A (ja) 2018-09-21 2024-08-15 癌を治療する方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024135623A Pending JP2024178159A (ja) 2018-09-21 2024-08-15 癌を治療する方法

Country Status (9)

Country Link
US (1) US20220125957A1 (enExample)
EP (1) EP3852816A4 (enExample)
JP (2) JP2022501441A (enExample)
KR (1) KR20210095620A (enExample)
CN (4) CN121338051A (enExample)
AU (2) AU2019345320B2 (enExample)
CA (1) CA3112806A1 (enExample)
IL (2) IL281600B2 (enExample)
WO (1) WO2020061458A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015073678A1 (en) 2013-11-14 2015-05-21 Endocyte, Inc. Compounds for positron emission tomography
MX2020010813A (es) 2018-04-17 2021-01-08 Endocyte Inc Metodos de tratamiento de cancer.
EP3972627A4 (en) 2019-05-20 2023-06-21 Endocyte, Inc. Methods for preparing psma conjugates
US11129912B1 (en) 2020-07-13 2021-09-28 POINT Biopharma Inc. Radiopharmaceutical and methods
JP2023539990A (ja) 2020-07-13 2023-09-21 ポイント バイオファーマ インコーポレイテッド 放射性薬剤および方法
WO2022106629A1 (en) 2020-11-19 2022-05-27 Novartis Ag Synthesis of prostate specific membrane antigen (psma) ligands

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016535013A (ja) * 2013-10-18 2016-11-10 ドイチェス クレブスフォルシュンクスツェントルム 前立腺特異的膜抗原（ｐｓｍａ）の標識インヒビター、前立腺癌の治療のための画像化剤および薬剤としてのその使用
WO2018108287A1 (en) * 2016-12-15 2018-06-21 The European Atomic Energy Community (Euratom), Represented By The European Commission Treatment of pmsa expressing cancers

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140154702A1 (en) * 2012-11-30 2014-06-05 Endocyte, Inc. Methods For Treating Cancer Using Combination Therapies
IL237525A (en) * 2015-03-03 2017-05-29 Shalom Eli Method for labeling a prostate-specific membrane antigen with a radioactive isotope
EP3400229B1 (en) * 2016-01-10 2024-03-06 Provincial Health Services Authority 18/19f-labelled compounds which target the prostate specific membrane antigen
DK3498308T3 (da) * 2017-12-13 2025-01-02 Sciencons AS Kompleks, der omfatter en psma-målrettet forbindelse bundet til et bly- eller thorium-radionuklid

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016535013A (ja) * 2013-10-18 2016-11-10 ドイチェス クレブスフォルシュンクスツェントルム 前立腺特異的膜抗原（ｐｓｍａ）の標識インヒビター、前立腺癌の治療のための画像化剤および薬剤としてのその使用
WO2018108287A1 (en) * 2016-12-15 2018-06-21 The European Atomic Energy Community (Euratom), Represented By The European Commission Treatment of pmsa expressing cancers

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, vol. 46, JPN6023029818, 19 September 2018 (2018-09-19), pages 129 - 138, ISSN: 0005114155 *
KRATOCHWIL C. ET AL., THE JOURNAL OF NUCLEAR MEDICINE, vol. 57, no. 8, JPN6023029819, 2016, pages 1170 - 1176, ISSN: 0005114154 *

Also Published As

Publication number Publication date
IL323981A (en) 2025-12-01
CN121338051A (zh) 2026-01-16
CN121154858A (zh) 2025-12-19
EP3852816A1 (en) 2021-07-28
CN113164631A (zh) 2021-07-23
IL281600A (en) 2021-05-31
KR20210095620A (ko) 2021-08-02
AU2026201845A1 (en) 2026-04-02
EP3852816A4 (en) 2022-07-13
CA3112806A1 (en) 2020-03-26
WO2020061458A1 (en) 2020-03-26
US20220125957A1 (en) 2022-04-28
AU2019345320B2 (en) 2025-12-11
IL281600B2 (en) 2026-03-01
IL281600B1 (en) 2025-11-01
JP2024178159A (ja) 2024-12-24
CN121130116A (zh) 2025-12-16
AU2019345320A1 (en) 2021-04-22

Similar Documents

Publication Publication Date Title
US20250235466A1 (en) Methods of treating cancer
AU2019345320B2 (en) Methods of treating cancer
JP7429688B2 (ja) シールド剤およびそれらの使用
US10751430B2 (en) Targeted radiotherapy chelates for in situ immune modulated cancer vaccination
RU2825637C2 (ru) Способы лечения рака
RU2811406C2 (ru) Способы лечения рака
JP2025513179A (ja) 小細胞肺がんの併用治療
HK40047004A (en) Methods of treating cancer

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220916

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220916

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230725

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231017

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240116

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240416

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240815

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20241015

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20241129

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20250115